Altresyn rebranded as OvaMed following acquisition from Ceva

Bimeda Inc. is pleased to announce the renaming of its altrenogest product for horses.

The product, formerly marketed as Altresyn was recently acquired from Ceva Animal Health as part of Bimeda’s strategic expansion into the equine segment.

“The trade name OvaMed more closely aligns with Bimeda’s brand identity and is a key step in the integration of the recently-acquired equine products within our portfolio and global brand” said Emmanuelle Lemaire-Galliot, Marketing Manager for Bimeda North America.

OvaMed is currently shipping to Bimeda’s distributors to fulfill veterinary orders.